Flex Health Outsources To A Medtech Industry In Flux

Flex Health Solutions' role in the medtech space is helping other companies develop superior products for the broadest market appeal. Its ability to source ideas for medical design from other parts of its $24 billion business means it is already leveraging the Fourth Industrial Revolution, just at the point that the industry is undergoing dramatic change.

IV1702_FlexImage_1200x675

Commoditization, price pressures and regulation. Draw a picture with these three labels around the edges, all pointing inward, and guess the industry that goes in the center of the diagram. Right now, it is the health care products industry – and medtech in particular. It's a picture that many other industries are already familiar with.

How medtech deals with the new situation it is finding itself in is the talking point in the industry, bar...

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

More from Manufacturing Focus

Why CAR T Therapies Are Hard To Scale, And How Challenges Can Be Solved

 

Chimeric antigen receptor T-cell (CAR-T) therapies have revolutionized the treatment of blood cancer, but scalability remains a major challenge. Experts explain how technologies such as chip-based miniaturized models and automation could be part of the solution.  

How Cellino’s Cassette Technology Will Impact Regenerative Medicine

 
• By 

Co-founder and CEO of Cellino Biotech, Nabiha Saklayen, discusses the company’s innovative platform which uses automated technologies to overcome challenges in the development of regenerative medicine.

Agnė Vaitkevičienė: The Versatile CEO Driving Memel Biotech

 

Rising star Agnė Vaitkevičienė is juggling roles as the CEO of an emerging Lithuanian biotech, with work for a partner company, the national biotech trade association and much more.   

China VBP, Localization And Other Strategies - How Far And Which Way?

 
• By 

Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues. 

More from In Vivo

Clone Test Oncology’s Next Decade: The Therapies And Players Reshaping A $400bn Future - Clone

 

Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.

In Vivo’s 2026 Rising Leaders-Part 1

 
• By 

The seventh annual edition of In Vivo’s Rising Leaders features entrepreneurs, academics, lawyers, regulators and innovators from around the globe, representing the forefront of creativity in health care.

XXXXtesting

 
• By 

XXXXtesting